Abstract

Rising R&D costs and drug patent expirations are driving consolidation in the life sciences industry. At the same time, companies are pushing for internal R&D productivity and acceleration, and they are focusing on cost cutting, especially in business processes not directly related to R&D or sales and marketing, such as procurement, supply chain, and manufacturing. Meanwhile, there is also greater attention to patient-oriented marketing and overall sales and marketing productivity and effectiveness. [To view the full article, please click here.]